Exchange: NASDAQ·Updated 07:52 PM EDT
News
all
press releases
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.65% on an annualized basis producing an average annual return of 14.88%. Currently, Amgen has a market capitalization of $223.91 billion.read more...
Benzinga
More News
Chubb, Toast And A Health Care Stock On CNBC's 'Final Trades'
Bill Baruch chose Amgen Inc. as his final trade, citing its strong Q2 results and raised guidance. Malcolm Ethridge recommended Chubb.read more...
Benzinga
Quantinuum's First Earnings After its IPO: Buy or Sell QNT Stock?
Quantinuum's first post-IPO earnings could reveal commercialization progress, bookings and spending trends as investors gauge execution in quantum computing.
Zacks
Upcoming Dividend Run For AMGN?
This morning a "Potential Dividend Run Alert" went out for Amgen Inc (NASD: AMGN), at our DividendChannel.com Dividend Alerts service (a free email alerts feature). Let's look at the situation in greater detail, shall we? First of all, what is a "Dividend Run" anyway? This is...
Nasdaq News: Markets
Company News for Aug 6, 2026
Companies In The News Are: AMGN, ANET, WYNN< BKNG.
Zacks
Notable Wednesday Option Activity: AMGN, DDOG, APP
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN), where a total of 13,905 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 56.5% of A...
Nasdaq News: Markets
AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.
Zacks
AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline
Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.
Zacks
Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive
IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.
Stocktwits
Amgen (AMGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks

Advertisement|Remove ads.